MedPath

Cardiovascular Responses in Congestive Heart Failure With Cheyne- Stokes Respiration

Not Applicable
Completed
Conditions
Heart Failure, Congestive
Cheyne-Stokes Respiration
Interventions
Procedure: Experimental lung function test
Registration Number
NCT00495196
Lead Sponsor
ResMed
Brief Summary

The purpose of the trial is to investigate the cardiovascular response to peripheral chemoreceptor stimulation in Congestive Heart Failure with Cheyne- Stokes Respiration

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
50
Inclusion Criteria
  • Moderate to severe heart failure (NYHA Class II or above) on optimal medical therapy
  • LVEF less than or equal to 45%
  • Stable condition as defined as no hospital admission or changes to medical therapy within two weeks prior to enrolment
Exclusion Criteria
  • Patients taking known respiratory stimulants or depressants
  • Clinically significant asthma requiring therapy
  • Significant parenchymal lung disease
  • Primary pulmonary hypertension
  • Myocardial infarction within three months prior to enrolment
  • Patients with cardiac resynchronisation devices and permanent pacemakers
  • Anaemic (haemoglobin < 12g/dL)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1Experimental lung function test-
2Experimental lung function test-
Primary Outcome Measures
NameTimeMethod
Cardiovascular parameters such as continuous blood pressure and heart rate.During administration of the intervention
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Royal Prince Alfred Hospital

🇦🇺

Camperdown, New South Wales, Australia

© Copyright 2025. All Rights Reserved by MedPath